Posted by Michael Wonder on 12 May 2021
NICE rejects Pfizer’s rare heart disease treatment Vyndaqel
12 May 2021 - Pfizer’s Vyndaqel has been rejected by NICE as a treatment for the rare heart condition transthyretin amyloidosis with cardiomyopathy.
The final guidance publication comes following an appeal against earlier draft recommendations by Pfizer, Cardiomyopathy UK and the British Society for Heart Failure, NICE said in a statement.
In the UK, around 800 people live with transthyretin amyloidosis with cardiomyopathy, a rare, under-diagnosed and life-threatening disease characterised by the buildup of abnormal deposits of misfolded protein called amyloid in the heart.
